NCT06310330 TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
| NCT ID | NCT06310330 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Norwegian University of Science and Technology |
| Condition | Breast Neoplasm Malignant Primary |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-03-08 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2024-03-08 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.
Eligibility Criteria
Inclusion Criteria: * Breast cancer and referral for follow-up to identify potential CTRCD Exclusion Criteria: * Not willing or able to consent
Contact & Investigator
Espen Holte, MD, PhD
PRINCIPAL INVESTIGATOR
St. Olavs Hospital
Frequently Asked Questions
Who can join the NCT06310330 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Neoplasm Malignant Primary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06310330 currently recruiting?
Yes, NCT06310330 is actively recruiting participants. Contact the research team at espen.holte@stolav.no for enrollment information.
Where is the NCT06310330 trial being conducted?
This trial is being conducted at Trondheim, Norway.
Who is sponsoring the NCT06310330 clinical trial?
NCT06310330 is sponsored by Norwegian University of Science and Technology. The principal investigator is Espen Holte, MD, PhD at St. Olavs Hospital. The trial plans to enroll 250 participants.